Adaptive Biotechnologies CSO sells 386,240 shares

Adaptive Biotechnologies Corp Chief Scientific Officer Harlan S. Robins reported open-market sales of 386,240 shares of common stock on July 2, 2026.

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp Chief Scientific Officer Harlan S. Robins reported open-market sales of 386,240 shares of common stock on July 2, 2026. The sales occurred in two blocks at weighted-average prices of $21.74 and $22.45 per share.

The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2026, indicating they were scheduled in advance rather than timed discretionarily. After these sales, he continues to hold a significant direct equity position in the company.

Insider Trade Summary 10b5-1

Net Seller: 386,240 shares

Net Sell 2 txns

Insider ROBINS HARLAN S

Role Chief Scientific Officer

Sold 386,240 shs ($8.50M)

Type	Security	Shares	Price	Value
Sale	Common Stock	239,351	$21.74	$5.20M
Sale	Common Stock	146,889	$22.45	$3.30M

Holdings After Transaction: Common Stock — 1,019,658 shares (Direct)

Footnotes (3)

1. F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026.
2. F2. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.15 to $22.145, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
3. F3. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $22.15 to $22.75, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

Key Figures

Total shares sold: 386,240 shares First block sold: 146,889 shares at $22.45 Second block sold: 239,351 shares at $21.74 +2 more

5 metrics

Total shares sold 386,240 shares Open-market sales on July 2, 2026

First block sold 146,889 shares at $22.45 Common stock, open-market sale

Second block sold 239,351 shares at $21.74 Common stock, open-market sale

Net share change -386,240 shares Net buy/sell direction reported as net-sell

Rule 10b5-1 plan adoption date March 13, 2026 Plan governing the reported trades

Key Terms

Rule 10b5-1 trading plan, weighted-average price, open-market sale, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted-average price financial

"The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions..."

Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.

open-market sale financial

"transaction_action: "open-market sale", transaction_code_description: "Sale in open market or private transaction""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan..."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Adaptive Biotechnologies (ADPT) report for Harlan S. Robins?

Adaptive Biotechnologies reported that Chief Scientific Officer Harlan S. Robins sold 386,240 shares of common stock in two open-market transactions on July 2, 2026, at weighted-average prices of $21.74 and $22.45 per share, according to a Form 4 filing.

At what prices did the Adaptive Biotechnologies (ADPT) CSO sell shares?

Harlan S. Robins sold shares at weighted-average prices of $21.74 and $22.45 per share. Footnotes note the trades occurred in multiple transactions within price ranges from $21.15 to $22.75, with detailed breakdowns available on request from the company or the SEC staff.

How many Adaptive Biotechnologies (ADPT) shares did the CSO sell in total?

The Form 4 shows total open-market sales of 386,240 shares of Adaptive Biotechnologies common stock. These sales were split into two transactions: 146,889 shares in one block and 239,351 shares in another, both executed on July 2, 2026.

Were the Adaptive Biotechnologies (ADPT) insider sales pre-planned under Rule 10b5-1?

Yes. A footnote states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by Harlan S. Robins on March 13, 2026. Such pre-planned programs schedule trades in advance, reducing the significance of short-term market timing.

Who is the insider involved in the recent Adaptive Biotechnologies (ADPT) Form 4 filing?

The insider is Harlan S. Robins, Chief Scientific Officer of Adaptive Biotechnologies Corp. The Form 4 indicates he holds the position of officer and completed the reported common stock sales in his capacity as a direct shareholder in the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/07/2026 - 06:52 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROBINS HARLAN S

(Last) (First) (Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVENUE EAST

(Street)

SEATTLE WASHINGTON 98109

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/02/2026		S(1)		239,351	D	$21.74(2)	1,166,547	D
Common Stock	07/02/2026		S(1)		146,889	D	$22.45(3)	1,019,658	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026.

2. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.15 to $22.145, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

3. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $22.15 to $22.75, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

	/s/ Harlan S Robins by Kyle Piskel, Attorney-in-Fact	07/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)